Phase 3 RCT in 542 patients with untreated advanced nonsquamous NSCLC: tiragolumab plus atezolizumab and chemotherapy did not improve PFS (median 8.3 vs 9.9 months) or OS (18.9 vs 23.1 months) vs pembrolizumab and chemotherapy; trial terminated.
RCTn = 542
Socinski et al. Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial